Do analysts rate BGM or INTS?

Intensity Therapeutics has a consensus target price of $37.50, indicating a potential upside of 830.52%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intensity Therapeutics is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Intensity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has preferable valuation and earnings, BGM or INTS?

BGM Group has higher revenue and earnings than Intensity Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $25.10M 1.45 -$1.44M N/A N/A Intensity Therapeutics N/A N/A -$11.61M -$5.71 N/A

Is BGM or INTS more profitable?

BGM Group's return on equity of 0.00% beat Intensity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets BGM Group N/A N/A N/A Intensity Therapeutics N/A -136.82% -105.82%

Do analysts rate ZYBT or INTS?

Intensity Therapeutics has a consensus price target of $37.50, indicating a potential upside of 830.52%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intensity Therapeutics is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Intensity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has stronger valuation and earnings, ZYBT or INTS?

Zhengye Biotechnology has higher revenue and earnings than Intensity Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $16.64M 1.97 -$9.98M N/A N/A Intensity Therapeutics N/A N/A -$11.61M -$5.71 N/A

Is ZYBT or INTS more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat Intensity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Zhengye Biotechnology N/A N/A N/A Intensity Therapeutics N/A -136.82% -105.82%

Which has stronger earnings and valuation, INTS or ABVC?

ABVC BioPharma is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Intensity Therapeutics N/A N/A -$11.61M -$5.71 N/A ABVC BioPharma N/A N/A -$7.91M -$0.40 N/A

Is INTS or ABVC more profitable?

ABVC BioPharma's return on equity of -62.46% beat Intensity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Intensity Therapeutics N/A -136.82% -105.82% ABVC BioPharma N/A -62.46% -39.99%

Intensity Therapeutics (INTS) Competitors

$4.03 -0.07 (-1.71%)

Closing price 04:00 PM Eastern

Extended Trading

$4.00 -0.03 (-0.62%)

As of 05:21 PM Eastern

Compare

INTS vs. TELA, BGM, BTAI, ZYBT, and ABVC

Should you buy Intensity Therapeutics stock or one of its competitors? MarketBeat compares Intensity Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Intensity Therapeutics include TELA Bio (TELA), BGM Group (BGM), BioXcel Therapeutics (BTAI), Zhengye Biotechnology (ZYBT), and ABVC BioPharma (ABVC). These companies are all part of the "med - biomed/gene" industry.

How does Intensity Therapeutics compare to TELA Bio?

Intensity Therapeutics (NASDAQ:INTS) and TELA Bio (NASDAQ:TELA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Intensity Therapeutics has a beta of 2.78, meaning that its stock price is 178% more volatile than the broader market. Comparatively, TELA Bio has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market.

In the previous week, TELA Bio had 1 more articles in the media than Intensity Therapeutics. MarketBeat recorded 2 mentions for TELA Bio and 1 mentions for Intensity Therapeutics. TELA Bio's average media sentiment score of 1.44 beat Intensity Therapeutics' score of 0.94 indicating that TELA Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Intensity Therapeutics	Positive
TELA Bio	Positive

3.7% of Intensity Therapeutics shares are owned by institutional investors. Comparatively, 94.4% of TELA Bio shares are owned by institutional investors. 7.6% of Intensity Therapeutics shares are owned by company insiders. Comparatively, 5.1% of TELA Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Intensity Therapeutics has higher earnings, but lower revenue than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A
TELA Bio	$80.28M	0.41	-$38.83M	-$0.79	N/A

Intensity Therapeutics has a net margin of 0.00% compared to TELA Bio's net margin of -49.30%. Intensity Therapeutics' return on equity of -136.82% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-136.82%	-105.82%
TELA Bio	-49.30%	-1,320.81%	-55.83%

Intensity Therapeutics presently has a consensus target price of $37.50, indicating a potential upside of 830.52%. TELA Bio has a consensus target price of $2.20, indicating a potential upside of 201.12%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Intensity Therapeutics is more favorable than TELA Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Intensity Therapeutics beats TELA Bio on 9 of the 16 factors compared between the two stocks.

How does Intensity Therapeutics compare to BGM Group?

BGM Group (NASDAQ:BGM) and Intensity Therapeutics (NASDAQ:INTS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

In the previous week, BGM Group and BGM Group both had 1 articles in the media. BGM Group's average media sentiment score of 1.89 beat Intensity Therapeutics' score of 0.94 indicating that BGM Group is being referred to more favorably in the media.

Company	Overall Sentiment
BGM Group	Very Positive
Intensity Therapeutics	Positive

BGM Group has higher revenue and earnings than Intensity Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$25.10M	1.45	-$1.44M	N/A	N/A
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A

BGM Group's return on equity of 0.00% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Intensity Therapeutics	N/A	-136.82%	-105.82%

Intensity Therapeutics has a consensus target price of $37.50, indicating a potential upside of 830.52%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intensity Therapeutics is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

BGM Group has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market. Comparatively, Intensity Therapeutics has a beta of 2.78, indicating that its stock price is 178% more volatile than the broader market.

3.7% of Intensity Therapeutics shares are held by institutional investors. 58.7% of BGM Group shares are held by company insiders. Comparatively, 7.6% of Intensity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

BGM Group and Intensity Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Intensity Therapeutics compare to BioXcel Therapeutics?

Intensity Therapeutics (NASDAQ:INTS) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Intensity Therapeutics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-136.82%	-105.82%
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%

Intensity Therapeutics currently has a consensus target price of $37.50, indicating a potential upside of 830.52%. BioXcel Therapeutics has a consensus target price of $11.00, indicating a potential upside of 685.71%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intensity Therapeutics is more favorable than BioXcel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Intensity Therapeutics and Intensity Therapeutics both had 1 articles in the media. BioXcel Therapeutics' average media sentiment score of 1.87 beat Intensity Therapeutics' score of 0.94 indicating that BioXcel Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Intensity Therapeutics	Positive
BioXcel Therapeutics	Very Positive

3.7% of Intensity Therapeutics shares are held by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are held by institutional investors. 7.6% of Intensity Therapeutics shares are held by company insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Intensity Therapeutics has a beta of 2.78, meaning that its share price is 178% more volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market.

Intensity Therapeutics has higher earnings, but lower revenue than BioXcel Therapeutics. Intensity Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A
BioXcel Therapeutics	$680K	63.57	-$69.90M	-$5.75	N/A

Summary

Intensity Therapeutics beats BioXcel Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Intensity Therapeutics compare to Zhengye Biotechnology?

Zhengye Biotechnology (NASDAQ:ZYBT) and Intensity Therapeutics (NASDAQ:INTS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

In the previous week, Zhengye Biotechnology had 1 more articles in the media than Intensity Therapeutics. MarketBeat recorded 2 mentions for Zhengye Biotechnology and 1 mentions for Intensity Therapeutics. Intensity Therapeutics' average media sentiment score of 0.94 beat Zhengye Biotechnology's score of 0.43 indicating that Intensity Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Zhengye Biotechnology	Neutral
Intensity Therapeutics	Positive

Zhengye Biotechnology has a beta of -2.4, suggesting that its share price is 340% less volatile than the broader market. Comparatively, Intensity Therapeutics has a beta of 2.78, suggesting that its share price is 178% more volatile than the broader market.

3.7% of Intensity Therapeutics shares are held by institutional investors. 7.6% of Intensity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Intensity Therapeutics has a consensus price target of $37.50, indicating a potential upside of 830.52%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intensity Therapeutics is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Zhengye Biotechnology has higher revenue and earnings than Intensity Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	1.97	-$9.98M	N/A	N/A
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A

Zhengye Biotechnology's return on equity of 0.00% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Intensity Therapeutics	N/A	-136.82%	-105.82%

Summary

Intensity Therapeutics beats Zhengye Biotechnology on 8 of the 13 factors compared between the two stocks.

How does Intensity Therapeutics compare to ABVC BioPharma?

Intensity Therapeutics (NASDAQ:INTS) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

In the previous week, ABVC BioPharma had 1 more articles in the media than Intensity Therapeutics. MarketBeat recorded 2 mentions for ABVC BioPharma and 1 mentions for Intensity Therapeutics. ABVC BioPharma's average media sentiment score of 1.24 beat Intensity Therapeutics' score of 0.94 indicating that ABVC BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Intensity Therapeutics	Positive
ABVC BioPharma	Positive

ABVC BioPharma's return on equity of -62.46% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-136.82%	-105.82%
ABVC BioPharma	N/A	-62.46%	-39.99%

Intensity Therapeutics has a beta of 2.78, meaning that its share price is 178% more volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

ABVC BioPharma is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A
ABVC BioPharma	N/A	N/A	-$7.91M	-$0.40	N/A

3.7% of Intensity Therapeutics shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 7.6% of Intensity Therapeutics shares are held by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Intensity Therapeutics presently has a consensus price target of $37.50, suggesting a potential upside of 830.52%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Intensity Therapeutics is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

ABVC BioPharma beats Intensity Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Intensity Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INTS vs. The Competition

Export

Metric	Intensity Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.88M	$3.65B	$6.84B	$12.44B
Dividend Yield	N/A	2.22%	2.67%	6.11%
P/E Ratio	-0.71	21.29	25.83	24.36
Price / Sales	N/A	313.32	541.54	96.87
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	0.82	8.71	10.98	6.49
Net Income	-$11.61M	$23.87M	$3.57B	$336.61M
7 Day Performance	2.54%	4.23%	3.06%	0.90%
1 Month Performance	-8.20%	1.71%	0.72%	-0.36%
1 Year Performance	-49.78%	69.92%	36.82%	31.26%

Intensity Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INTS Intensity Therapeutics	3.8525 of 5 stars	$4.03 -1.7%	$37.50 +830.5%	-49.0%	$10.88M	N/A	N/A	2,021
TELA TELA Bio	3.6264 of 5 stars	$0.86 -4.3%	$2.20 +156.1%	-64.2%	$38.46M	$80.81M	N/A	120	Positive News Short Interest Decrease
BGM BGM Group	0.7701 of 5 stars	$0.39 -12.6%	N/A	-97.3%	$37.74M	$26.85M	N/A	298	Positive News
BTAI BioXcel Therapeutics	2.4068 of 5 stars	$1.19 -0.8%	$11.00 +824.4%	-26.0%	$36.75M	$680K	N/A	90	Positive News
ZYBT Zhengye Biotechnology	0.6325 of 5 stars	$0.78 -8.0%	N/A	-89.2%	$36.73M	$16.64M	N/A	278	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INTS) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intensity Therapeutics (INTS) Competitors

INTS vs. TELA, BGM, BTAI, ZYBT, and ABVC

How does Intensity Therapeutics compare to TELA Bio?

Summary

How does Intensity Therapeutics compare to BGM Group?

Summary

How does Intensity Therapeutics compare to BioXcel Therapeutics?

Summary

How does Intensity Therapeutics compare to Zhengye Biotechnology?

Summary

How does Intensity Therapeutics compare to ABVC BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INTS vs. The Competition

Intensity Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Intensity Therapeutics (INTS) Competitors

INTS vs. TELA, BGM, BTAI, ZYBT, and ABVC

How does Intensity Therapeutics compare to TELA Bio?

Which has more volatility and risk, INTS or TELA?

Does the media prefer INTS or TELA?

Do insiders and institutionals have more ownership in INTS or TELA?

Which has better valuation & earnings, INTS or TELA?

Is INTS or TELA more profitable?

Do analysts prefer INTS or TELA?

Summary

How does Intensity Therapeutics compare to BGM Group?

Does the media prefer BGM or INTS?

Which has preferable valuation and earnings, BGM or INTS?

Is BGM or INTS more profitable?

Do analysts rate BGM or INTS?

Which has more volatility & risk, BGM or INTS?

Do insiders & institutionals believe in BGM or INTS?

Summary

How does Intensity Therapeutics compare to BioXcel Therapeutics?

Is INTS or BTAI more profitable?

Do analysts recommend INTS or BTAI?

Does the media prefer INTS or BTAI?

Do insiders and institutionals hold more shares of INTS or BTAI?

Which has more volatility and risk, INTS or BTAI?

Which has higher valuation and earnings, INTS or BTAI?

Summary

How does Intensity Therapeutics compare to Zhengye Biotechnology?

Does the media prefer ZYBT or INTS?

Which has more volatility & risk, ZYBT or INTS?

Do insiders & institutionals hold more shares of ZYBT or INTS?

Do analysts rate ZYBT or INTS?

Which has stronger valuation and earnings, ZYBT or INTS?

Is ZYBT or INTS more profitable?

Summary

How does Intensity Therapeutics compare to ABVC BioPharma?

Does the media refer more to INTS or ABVC?

Is INTS or ABVC more profitable?

Which has more volatility and risk, INTS or ABVC?

Which has stronger earnings and valuation, INTS or ABVC?

Do insiders & institutionals have more ownership in INTS or ABVC?

Do analysts recommend INTS or ABVC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INTS vs. The Competition

Intensity Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools